Skip to main content
SpringerLink
Log in

Renal Involvement in Dysproteinemias

  • Chapter
Therapy of Renal Diseases and Related Disorders

  • 173 Accesses

Abstract

Within the term dysproteinemia are included a number of diseases characterized by B-cell proliferation with cell secretion of immunoglobulins (Ig) detected in the serum and/or urine. The two main diseases in this group are multiple myeloma and Waldenström’s disease. In AL amyloidosis, the amyloid substance is derived from Ig light chains. Frequently monoclonal Ig component or light chains (also called Bence Jones proteins, BJP) are found in the serum or urine. Other chemical types of amyloid substances have been identified and have been shown to derive from (or be associated with) serum components [serum A amyloid (SAA), protein, prealbumin or beta2 microglobulin; see below]. Some considerations on the management of amyloidosis have therefore been included in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kyle RA: Multiple myeloma. Review of 869 cases. Mayo Clin Proc 50:29–40, 1975.

    PubMed  CAS  Google Scholar 

  2. Galton DAG, Peto R: Report on the first myelomatosis trial. Part I. Analysis of presenting features of prognostic importance. Br J Haematol 24:123–139, 1973.

    Google Scholar 

  3. Alexanian R, Balcerzak S, Bonnet JD, Gehan EA, Haut A, Hewlett JS, Monto RW: Prognostic factors in multiple myeloma. Cancer 36:1192–1201, 1975.

    PubMed  CAS  Google Scholar 

  4. Fang LST: Light-chain nephropathy. Kidney Int 27:582–592, 1985.

    PubMed  CAS  Google Scholar 

  5. Kyle RA: Multiple myeloma: Current therapy and a glimpse of the future. Scand J Haematol 35:38–47, 1985.

    PubMed  CAS  Google Scholar 

  6. Van Breukelen FJM, Bijvoet OLM, Van Oosterom AT: Inhibition of osteolytic bone lesions by (3-amino-l-hydroxypropylidene)l, 1-bisphosphonate (APD). Lancet 1:803–805, 1979.

    PubMed  Google Scholar 

  7. Harinck HIJ, Bijvoet OLM, Plantingh AST, Body JJ, Elte JWF, Sleeboom HP, Wildiers J, Neijt JP: Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride. Am J Med 82: 1133–1142, 1987.

    PubMed  CAS  Google Scholar 

  8. Durie BGM, Salmon SE: A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival, Cancer 36:842–854, 1975.

    PubMed  CAS  Google Scholar 

  9. Powis G: Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs. Cancer Treat Rev 9:85–124, 1982.

    PubMed  CAS  Google Scholar 

  10. Weiss RB, Poster DS: The renal toxicity of cancer. Chemo-therapeutic agents. Cancer Treat Rev 9:37–52, 1982.

    PubMed  CAS  Google Scholar 

  11. Cornwell GG III, Pajak TF, Mclntyre OR, Kochwa S, Dosik H: Influence of renal failure on myelosuppressive effects of melphalan: Cancer and leukemia group B experience. Cancer Treat Rep 66:475–481, 1982.

    PubMed  Google Scholar 

  12. Reich SD: Clinical correlations of adriamycin pharmacology. Pharmacol Ther Part C 2:239–249, 1978.

    CAS  Google Scholar 

  13. Cohen AH, Border WA: Myeloma kidney. An immu-nomorphogenetic study of renal biopsies. Lab Invest 42: 248–256, 1980.

    PubMed  CAS  Google Scholar 

  14. Rota S, Mougenot B, Baudoin B, De Meyer-Brassur M, Lemaitre V, Michel C, Mignon F, Rondeau E, Vanhille P, Verroust P, Ronco P: Multiple myeloma and severe renal failure: A clinicopathologic study of outcome and prognosis in 34 patients. Medicine 66:126–137, 1987.

    PubMed  CAS  Google Scholar 

  15. Ganeval D, Cathomen M, Noel LH, Grunfeld JP: Kidney involvement in multiple myeloma and related disorders. Contr Nephrol 33:210–222, 1982.

    CAS  Google Scholar 

  16. MRC Working Party on Leukaemia in Adults: Analysis and management of renal failure in fourth MRC myelomatosis trial. Br Med J 288:1411–1416, 1984.

    Google Scholar 

  17. Melcion C, Mougenot B, Baudouin B, Ronco P, Moulon-guet-Doleris L, Vanhille Ph, Beaufils M, Morel-Maroger L, Verroust P, Richet G: Renal failure in myeloma: Relationship with isoelectric point of immunoglobulin light chains. Clin Nephrol 22:138–143, 1984.

    PubMed  CAS  Google Scholar 

  18. Cohen DJ, Sherman WH, Osserman EF, Appel GB: Acute renal failure in patients with multiple myeloma. Am J Med 76:247–256, 1984.

    PubMed  CAS  Google Scholar 

  19. Craig JB, Powell BL: Multiple myeloma. Arch Intern Med 144:863–864, 1984.

    PubMed  CAS  Google Scholar 

  20. Wu MJ, Kumar KS, Kulkarni G, Kaiser H: Multiple myeloma in naproxen-induced acute renal failure. N Engl J Med 317:170–171, 1987.

    PubMed  CAS  Google Scholar 

  21. Misiani R, Remuzzi G, Bertani T, Licini R, Levoni P, Crippa A, Mecca G: Plasmapharesis in the treatment of acute renal failure in multiple myeloma. Am J Med 66:684–688, 1979.

    PubMed  CAS  Google Scholar 

  22. Coward RA, Mallick NP, Delamore IW: Should patients with renal failure associated with myeloma be dialysed? Br Med J 287:1575–1578, 1983.

    CAS  Google Scholar 

  23. Diaz MA, Feliu J, Garcia Alegria J, Medrano J, Picazo ML, Barbado FJ, Ordonez A, Gil A, Vasques JJ: Fracaso renal agudo y mieloma multiple: Anàlisis de trece casos. Med Clin (Barc) 85:650–652, 1985.

    CAS  Google Scholar 

  24. Pasquali S, Cagnoli L, Rovinetti C, Rigotti A, Zucchelli P: Plasma exchange therapy in rapidly progressive renal failure due to multiple myeloma. Int J Artif Organs 8:27–30, 1985.

    PubMed  Google Scholar 

  25. Pozzi C, Pasquali S, Donini U, Casanova S, Banfi G, Tiraboschi G, Furci L, Porri MT, Ravelli M, Lupo A, Schena FP, Brunati C, Imbasciati E, Locatelli F: Prognostic factors and effectiveness of treatment in acute renal failure due to multiple myeloma: A review of 50 cases. Clin Nephrol 28:1–9, 1987.

    PubMed  CAS  Google Scholar 

  26. Feest TG, Burge PS, Cohen SL: Successful treatment of myeloma kidney by diuresis and plasmapheresis. Br Med J 1:503–504, 1976.

    PubMed  CAS  Google Scholar 

  27. Johnson WJ, Kyle RA, Dahlberg PJ: Dialysis in the treatment of multiple myeloma. Mayo Clin Proc 55:65–72, 1980.

    PubMed  CAS  Google Scholar 

  28. Cosio FG, Pence TV, Shapiro FL, Kjellstrand CM: Severe renal failure in multiple myeloma. Clin Nephrol 15:206–210, 1981.

    PubMed  CAS  Google Scholar 

  29. Brunner FP, Brynger H, Chantier C, Donckerwolcke RA, Hathway RA, Jacobs C, Selwood NH, Wing AJ: Combined report on regular dialysis and transplantation in Europe, IX. In: Proc Eur Dial Trans Assoc 16:2–73, 1978.

    Google Scholar 

  30. Brown WW, Hebert LA, Piering WF, Pisciotta AV, Leman J Jr, Garancis JC: Reversal of chronic end-stage renal failure due to myeloma kidney. Ann Iniern Med 90:793–794, 1979.

    CAS  Google Scholar 

  31. Dahlberg PJ, Newcomer KL, Yutuc WR, Smith MJ: Myeloma Kidney: Improved renal function following long-term chemotherapy and hemodialysis. Am J Nephrol 3:242–243, 1983.

    PubMed  CAS  Google Scholar 

  32. Humphrey RL, Wright JR, Zachary JB, Sterioff S, De Fronzo RA: Renal transplantation in multiple myeloma. Ann Intern Med 83:651–653, 1975.

    PubMed  CAS  Google Scholar 

  33. De Lima JJG, Kourilsky O, Meyrier A, Morel-Maroger L, Sraer JD: Kidney transplant in multiple myeloma. Early recurrence in the graft with sustained normal renal function. Transplantation 31:223–224, 1981.

    Google Scholar 

  34. Briefel GR, Spees EK, Humphrey RL, Hill GS, Sarai R, Zachary JB: Renal transplantation in a patient with multiple myeloma and light chain nephropathy. Surgery 93:579–584, 1983.

    PubMed  CAS  Google Scholar 

  35. Walker F, Bear RA: Renal transplantation in light-chain multiple myeloma. Am J Nephrol 3:34–37, 1983.

    PubMed  CAS  Google Scholar 

  36. Lazarus HM, Lederman M, Lubin A, Herzig RG, Schiffman G, Jones P, Wine A, Rodman HM: Pneumococcal vaccination: The response of patients with multiple myeloma.

    Google Scholar 

  37. Morel-Maroger L, Beaufils M, Richet G: The kidney in dysproteinemias. In: J Hamburger J, Crosnier J, JP Grunfeld, ed, Nephrology. John Wiley and Sons, New York, pp 711–726, 1979.

    Google Scholar 

  38. Morel-Maroger L, Basch A, Danon F, Verroust P, Richet G: Pathology of the kidney in Waldenstrom’s macro-globulinemia. N Engl J Med 283:123–129, 1970.

    PubMed  CAS  Google Scholar 

  39. Morel-Maroger L, Verroust P: Glomerular lesions in dysproteinemias. Kidney Int 5:249–252, 1974.

    PubMed  CAS  Google Scholar 

  40. Gallo GR, Feiner HD, Buxbaum JN: The kidney in lymphoplasmacytic disorders. In: SC Sommers, PP Rosen eds, Pathology Annual Appleton-Century-Crofts, Norwalk, CT, Part 1, Vol 17, pp 291–317, 1982.

    Google Scholar 

  41. Hill GS: Multiple myeloma, amyloidosis, Waldenström’s macroglobulinemia, cryoglobulinemias, and benign monoclonal gammopathies. In: RH Heptinstall, ed, Pathology of the Kidney, Little, Brown, Boston pp 993–1067, 1983.

    Google Scholar 

  42. Martelo OJ, Shultz DR, Pardo V, Perez-Stable E: Immunologically-mediated renal disease in Waldenström’s macroglobulinemia. Am J Med 58:567–575, 1975.

    PubMed  CAS  Google Scholar 

  43. Faraggiana T, Parolini C, Previato G, Lupo A: Light and electron microscopic findings in five cases of cryo-globulinemic glomerulonephritis. Virchows Arch A [Path Anat Histol] 384:29–44, 1979.

    CAS  Google Scholar 

  44. Kyle RA: Diagnosis and management of multiple myeloma and related disorders. Prog Hematol 14:257–282, 1986.

    PubMed  CAS  Google Scholar 

  45. Kyle RA: Monoclonal gammopathy of undetermined significance: Natural history in 241 cases. Am J Med 64:814–826, 1978.

    PubMed  CAS  Google Scholar 

  46. Smithline N, Kassirer JP, Cohen JJ: Light-chain nephropathy renal tubular dysfunction associated with light-chain proteinuria. N Engl J Med 294:71–74, 1976.

    PubMed  CAS  Google Scholar 

  47. Preuss HG, Hammack WJ, Murdaugh HV: The effect of Bence Jones protein on the in vitro function of rabbit renal cortex. Nephron 5:210–216, 1967.

    Google Scholar 

  48. Ganeval D, Noel LH, Preud’Homme JL, Droz D, Grunfeld JP: Light-chain deposition disease: Its relation with Al-type amyloidosis. Kidney Int 26:1–9, 1984.

    PubMed  CAS  Google Scholar 

  49. Noel LH, Droz D, Ganeval D, Grunfeld JP: Renal granular monoclonal light chain deposits: Morphological aspects in 11 cases. Clin Nephrol 21:2163–2169, 1984.

    Google Scholar 

  50. Randall RE, Williamson WC, Mullinax F, Tung MY, Still WJS: Manifestations of systemic light chain deposition. Am J Med 60:293–299, 1976.

    PubMed  CAS  Google Scholar 

  51. Ganeval D, Mignon F, Preud’Homme JL, Noel LH, Morel-Maroger L, Droz D, Brouet JC, Mery J Ph, Grunfeld JP: Visceral deposition of monoclonal light chains and immunoglobulins: A study of renal and immunopathologic abnormalities. In: J Hamburger J, Crosnier J, JP Grunfeld, MH Maxwell, eds, Advances in Nephrology, Vol 11, Year Book Medical Publishers, Chicago pp 25–63, 1982.

    Google Scholar 

  52. Preud’Homme JL, Morel-Maroger L, Brouet JC, Cerf M, Mignon F, Guglielmi P, Seligmann M: Synthesis of abnormal immunoglobulins in lymphoplasmacytic disorders with visceral light chain deposition. Am J Med 69:703–710, 1980.

    PubMed  Google Scholar 

  53. Seymour AE, Thompson AJ, Smith PS, Woodroffe AJ, Clarkson AR: Kappa light chain glomerulosclerosis in multiple myeloma. Am J Pathol 101:557–580, 1980.

    PubMed  CAS  Google Scholar 

  54. Tubbs RR, Gephardt GN, McMahon JT, Hall PF, Valenzuela R, Vidt DG: Light chain nephropahty. Am J Med 71:263–269, 1981.

    PubMed  CAS  Google Scholar 

  55. Droz D, Noel LH, Carnot F, Degos F, Ganeval D, Grunfeld JP: Liver involvement in nonamyloid light chain deposits disease. Lab Invest 50:683–689, 1984.

    PubMed  CAS  Google Scholar 

  56. Gipstein RM, Cohen AH, Adams DA, Adams T, Grabie MT: Kappa light chain nephropathy without evidence of myeloma cells. Response to chemotherapy with cessation of maintenance hemodialysis. Am J Nephrol 2:276–281, 1982.

    PubMed  CAS  Google Scholar 

  57. Gerlag PGG, Koene RAP, Berden JHM: Renal transplantation in light chain nephropathy: Case report and review of the literature. Clin Nephrol 25:101–104, 1986.

    PubMed  CAS  Google Scholar 

  58. Case Records of the Massachusetts General Hospital (Case 1–1981): N Engl J Med 304:33–43, 1981.

    Google Scholar 

  59. Husby G, Sletten K: Chemical and clinical classification of amyloidosis 1985. Scand J Immunol 23:253–265, 1986.

    PubMed  CAS  Google Scholar 

  60. Mery J Ph, Mostefa S: Remission in renal amyloidosis. Ann Intern Med 83:581, 1975.

    PubMed  CAS  Google Scholar 

  61. Pras M, Gafni J, Jacob ET, Cabili S, Zemer D, Sohar E: Recent advances in Familial Mediterranean Fever. In: JP Grunfeld, MH Maxwell, eds, Advances in Nephrology, Vol 13, Year Book Medical Publishers, Chicago, pp 261–270, 1984.

    Google Scholar 

  62. Karsenty G, Ulmann A, Droz D, Carnot F, Grunfeld JP: Clinical and histological resolution of systemic amyloidosis after renal cell carcinoma removal. Nephron 40:232–234, 1985.

    PubMed  CAS  Google Scholar 

  63. Lowenstein J, Gallo G: Remission of the nephrotic syndrome in renal amyloidosis. N Engl J Med 282:128–132, 1970.

    PubMed  CAS  Google Scholar 

  64. Michael J, Jones NF: Spontaneous remissions of nephritic syndrome in renal amyloidosis. Br Med J 1:1592–1593, 1978.

    PubMed  CAS  Google Scholar 

  65. Thoenes W, Schneider HM: Human glomerular amyloidosis with special regard to proteinuria and amyloidogenesis. Klin Wochenschr 58:667–680, 1980.

    PubMed  CAS  Google Scholar 

  66. Dikman SH, Churg J, Kahn T: Morphologic and clinical correlates in renal amyloidosis. Hum Pathol 12:160–169, 1981.

    PubMed  CAS  Google Scholar 

  67. Janssen S, Van Rijswijk MH, Meijer S, Ruinen L, Van Der Hem GK: Clinical evaluation of AA and AL amyloid disease. In: J Marrink, MH Van Rijswijk, eds, Amyloidosis. Martinus Nijhoff, Boston, pp 61–72, 1986.

    Google Scholar 

  68. Fain O, Ganeval D, Roija L, Kreis H, Noel LH, Barbanel C, Vantelon J, Hannedouche T: Prognostic factors in 63 patients with amyloidosis and renal involvement (abstract). XXIVth Congr Europ Dial Transpl Assoc Europ Renal Assoc Berlin (West), in press, 1987.

    Google Scholar 

  69. Pasqualis, Zucchelli P, Cagnoli L, Confalonieri R, Pozzi C, Banfi G, Lupo A, Bertani T: Renal histological lesions and clinical syndromes in multiple myeloma. Clin Nephrol 27: 222–228, 1987.

    PubMed  Google Scholar 

  70. Libbey CA, Skinner M, Cohen AS: Use of abdominal fat tissue aspirate in the diagnosis of systemic amyloidosis. Arch Intern Med 143:1549–1552, 1983.

    PubMed  CAS  Google Scholar 

  71. Duston MA, Skinner M, Shirahama T, Cohen AS: Diagnosis of amyloidosis by abdominal fat aspiration. Analysis of four years’ experience. Am J Clin Pathol 87:756–761, 1987.

    Google Scholar 

  72. Noel LH, Droz D, Ganeval D: Immunohistochemical characterization of renal amyloidosis..Am J Clin Pathol 87:756–761, 1987.

    PubMed  CAS  Google Scholar 

  73. Gise HV, Helmchen U, Mikeler E, Bruning L, Walther CH, Christ H, Mackensen S, Bohle A: Correlations between the morphological and clinical findings in a patient recovering from secondary generalised amyloidosis with renal involvement. Virchows Arch A [Path Anat Histol] 379:119–129, 1978.

    Google Scholar 

  74. Falck HM, Tornroth T, Skifvars B, Wecelius O: Resolution of renal amyloidosis secondary to rheumatoid arthritis. Acta Med Scand 205:651–656, 1979.

    PubMed  CAS  Google Scholar 

  75. Triger DR, Joekes AM: Renal amyloidosis. A fourteen year follow-up. Q J Med 42:15–40, 1973.

    PubMed  CAS  Google Scholar 

  76. Dikman SH, Kahn T, Gribetz D, Churg J: Resolution of renal amyloidosis. Am J Med 63:430–433, 1977.

    PubMed  CAS  Google Scholar 

  77. Jacquot Ch, D’Auzac Ch, Loirat Ph, Bariety J: Aggravation foudroyante d’amylose rénale après chirurgie. Trois observations. Nouv Press Med 10:3389–3395, 1981.

    CAS  Google Scholar 

  78. Ekenstam E, Michaelsson G, Hallgren R: Response of secondary amyloidosis in psoriasis to treatment with etretinate and ultraviolet light. Br Med J 293:733–734, 1986.

    Google Scholar 

  79. Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J: Colchicine in the prevention and treatment of the amyloidosis of Familial Mediterranean Fever. N Engl J Med 314: 1001–1005, 1986.

    CAS  Google Scholar 

  80. Cohen AS, Shirahama T, Sipe JD, Skinner M: Amyloid proteins, precursors, mediator, and enhancer. Lab Invest 48:1–4, 1983.

    PubMed  CAS  Google Scholar 

  81. Shirahama T, Cohen AS: Blockage of amyloid induction by colchicine in an animal model. J Exp Med 140:1102–1107, 1974.

    CAS  Google Scholar 

  82. Cohen AS, Rubinow A, Anderson JJ, Skinner M, Mason JH, Libbey C, Kayne H: Survival of patients with primary (AL) amyloidosis. Colchicine-treated cases from 1976 to 1983 compared with cases seen in previous years (1961 to 1973). Am J Med 82:1182–1190, 1987.

    PubMed  CAS  Google Scholar 

  83. Cohen HJ, Lessin LS, Hallal J, Burkholder P: Resolution of primary amyloidosis during chemotherapy. Studies in a patient with nephrotic syndrome. Ann Intern Med 82:466–473, 1975.

    PubMed  CAS  Google Scholar 

  84. Buxbaum JN, Hurley ME, Chuba J, Spiro T: Amyloidosis of the AL type. Clinical, morphologic and biochemical aspects of the response to therapy with alkylating agents and prednisone. Am J Med 67:867–878, 1979.

    PubMed  CAS  Google Scholar 

  85. Kyle RA, Wagoner RD, Holley KE: Primary systemic amyloidosis. Resolution of the nephrotic syndrome with melphalan and prednisone. Arch Intern Med 142:1445–1447, 1982.

    PubMed  CAS  Google Scholar 

  86. Gertz MA, Kyle RA: Response of primary hepatic amyloidosis to melphalan and prednisone: A case report and review of the literature. Mayo Clin Proc 61:218–223, 1986.

    PubMed  CAS  Google Scholar 

  87. Kyle RA, Greipp PR: Primary systemic amyloidosis: Comparison of melphalan and prednisone versus placebo. Blood 52:818–827, 1978.

    PubMed  CAS  Google Scholar 

  88. Kyle RA, Greipp PR, Garton JP, Gertz MA: Primary systemic amyloidosis. Comparison of melphalan/prednisone vs. colchicine. Am J Med 79:708–716, 1985.

    PubMed  CAS  Google Scholar 

  89. Kedar (Keizman) I, Greenwald M, Ravid M: Treatment of experimental murine amyloidosis with dimethylsulphoxide. Eur J Clin Invest 7:149–150, 1977.

    PubMed  CAS  Google Scholar 

  90. Kisilevsky R, Boudreau L, Foster D: Kinetics of amyloid deposition. II. The effects of dimethylsulfoxide and colchicine therapy. Lab Invest 48:60–67, 1983.

    PubMed  CAS  Google Scholar 

  91. Ravid M, Kedar (Keizman) I, Sohar E: Effect of a single dose of dimethylsulphoxide on renal amyloidosis. Lancet 2:730–731, 1977.

    Google Scholar 

  92. Ravid M, Shapira J, Lang R, Kedar I: Prolonged dimethylsulphoxide treatment in 13 patients with systemic amyloidosis. Ann Rheum Dis 41:587–592, 1982.

    PubMed  CAS  Google Scholar 

  93. Cameron JS: Coagulation and thromboembolic complications in the nephrotic syndrome. In: JP Grunfeld, MH Maxwell, eds, Advances in Nephrology, Vol 13, Year Book Medical Publishers, Chicago, pp 75–114, 1984.

    Google Scholar 

  94. Ben Ari J, Zlotnik M, Oren A, Berlyne GM Dialysis in renal failure caused by amyloidosis of Familial Mediterranean Fever. A report to ten cases. Arch Intern Med 136: 449–451, 1976.

    Google Scholar 

  95. Jones NF Renal amyloidosis: Pathogenesis and therapy. Clin nephrol 6:459–464, 1976.

    PubMed  CAS  Google Scholar 

  96. Hamblin TG: the kidney in myeloma. Br J Med 292:2–3, 1976.

    Google Scholar 

  97. Wheeler DC, Feehally J, Burton P, Walls J: The kidney in myeloma. Br Med J 292:339, 1986.

    Google Scholar 

  98. Cohen AS, Bricetti AB, Harringto JT, Mannick: Renal transplantation in two cases of amyloidosis. Lancet 2:513–516, 1971.

    PubMed  CAS  Google Scholar 

  99. Jacob ET, Bar-Nathan N, Shapira Z Renal transplantation in the amyloidosis of Familial Mediterranean Fever. Arch Intern Med 139:1135–1138, 1979.

    PubMed  CAS  Google Scholar 

  100. Kuhlback B, Falck H, Tornroth T, Wallenius M, Lindstrom BL, Pasternack A: Renal transplantation in amyloidosis. Acta Med Scand 205:169–172, 1979.

    PubMed  CAS  Google Scholar 

  101. Jacob ET, Siegal B, Bar-Nathan N, Gafni J: Improving outlook for renal transplantation in amyloid nephropathy. Transpl Proc 14:41–45, 1982.

    Google Scholar 

  102. Cuvelier R, Pirson Y, Cosyns JP, Squifflet JP, Alexandre GPJ, Van Ypersele De Strihou C: Transplantation rénale en cas d’amylose. Néphrologie 7:63–66, 1986.

    PubMed  CAS  Google Scholar 

  103. Kyle RA, Greipp PR: Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc 58:665–683, 1983.

    PubMed  CAS  Google Scholar 

  104. Falk RH, Plehn JF, Deering T, Shick EC Jr, Boinay P, Rubinow A, Skinner M, Cohen AS: Sensitivity and specificity of the echocardiographic features of cardiac amyloidosis. Am J Cardiol 59:418–422, 1987.

    PubMed  CAS  Google Scholar 

  105. Gertz MA, Skinner M, Connors LH, Falk RH, Cohen AS, Kyle RA: Selective binding of nifedipine to amyloid fibrils. Am J Cardiol 55:1646, 1985.

    PubMed  CAS  Google Scholar 

  106. Camoriano JK, Greipp PR, Bayer GK, Bowie EJW: Resolution of acquired factor X deficiency and amyloidosis with melphalan and prednisone therapy. N Engl J Med 316:1133–1135, 1987.

    PubMed  CAS  Google Scholar 

  107. Van Ypersele De Strihou C, Honhon B, Vandenbroucke JM, Huaux JP, Noel H, Maldague B: Dialysis amyloidosis. In: JP Grunfeld, MH Maxwell, eds, Advances in Nephrology, Vol 17. Year Medical Book Publishers, Chicago, pp 401–421, 1988.

    Google Scholar 

  108. Brouet JC, Clauvel, JP, Danon F, Klein M, Seligmann M: Biological and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 57:775–788, 1974.

    PubMed  CAS  Google Scholar 

  109. Cordonnier D, Vialtel P, Renversez J CH, Chenais F, Favre M, Tournoud A, Barioz C, Bayle F, Dechelette E, Denis Mc, Couderc P: Renal disease in 18 patients with mixed type II IgM-IgG cryoglobulinemia: Monoclonal lymphoid infiltration (2 cases) and membranoproliferative glomerulone-phritis (14 cases). In: J Hamburger, J Crosnier, JP Grunfeld, MH Maxwell, eds, Advances in Nephrology, Vol 12, Year Book Medical Publishers, Chicago, pp 177–204, 1983.

    Google Scholar 

  110. D’Amico G, Colasanti G, Ferrado F, Sinico AR, Bucci A, Fornasier A: Renal involvement in essential mixed crylgol-bulinemia: A peculiar type of immune-mediated renal disease. In: JP Grunfeld, MH Maxwell, eds, Advances in Nephrology, Vol 17. Year Book Medical Publishers, Chicago, pp 219–239, 1988.

    Google Scholar 

  111. Tarantino A, Montagnino G, Baldassari A, Barbiano DI, Belgio-Joso G, Colasanti G, Montoli A, Bucci A, Ponticelli C: Prognostic factors in essential mixed cryoglobulinemia nephropathy. In: Antiglobulins, Cryoglobulins and Glomerulonephritis. C Ponticelli, L Minetti, G D’Amico, eds, Martinus Nijhoff, Boston pp 219–225, 1986.

    Google Scholar 

  112. Pusey CK, Schifferli JA, Lockwood CM: Use of plasma exchange in the management of mixed essential cryoglobulinemia. Artif Organs 5:183–187, 1981.

    Google Scholar 

  113. De Vecchi A, Montagnino G, Pozzi G, Tarantino A, Locatelli F, Ponticelli C: Intravenous methylprednisolone pulse therapy in essential mixed cryoglobulinemia nephropathy. Clin Nephrol 19:221–22, 1983.

    Google Scholar 

Download references

Authors
  1. Dominique Ganeval
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-Pierre Grünfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Baylor College of Medicine, The Methodist Hospital, Houston, Texas, USA

    Wadi N. Suki

  2. Division of Nephrology, University of Southern California, Los Angeles, California, USA

    Shaul G. Massry

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Kluwer Academic Publishers

About this chapter

Cite this chapter

Ganeval, D., Grünfeld, JP. (1991). Renal Involvement in Dysproteinemias. In: Suki, W.N., Massry, S.G. (eds) Therapy of Renal Diseases and Related Disorders. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0689-4_30

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-0689-4_30

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8027-9

  • Online ISBN: 978-1-4613-0689-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation